ELAN
Elanco Animal Health Incorporated NYSE Listed Sep 20, 2018$24.01
Mkt Cap $12.0B
52w Low $11.83
76.7% of range
52w High $27.72
50d MA $23.75
200d MA $21.63
P/E (TTM)
-47.9x
EV/EBITDA
21.8x
P/B
1.7x
Debt/Equity
0.6x
ROE
-3.5%
P/FCF
39.6x
RSI (14)
—
ATR (14)
—
Beta
1.88
50d MA
$23.75
200d MA
$21.63
Avg Volume
5.0M
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
2500 Innovation Way · Greenfield, IN 46140 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | BMO | 0.11 | 0.13 | +18.2% | 26.38 | +0.7% | +1.7% | -2.4% | +0.8% | -1.2% | -4.6% | — |
| Nov 5, 2025 | BMO | 0.13 | 0.19 | +46.2% | 21.60 | +0.6% | -0.4% | -0.1% | +3.6% | +2.6% | -3.5% | — |
| Aug 7, 2025 | BMO | 0.20 | 0.26 | +30.0% | 16.48 | +0.3% | +1.2% | +2.6% | +1.9% | +2.2% | +1.1% | — |
| May 7, 2025 | BMO | 0.31 | 0.37 | +19.4% | 12.01 | +0.6% | +2.2% | -2.6% | +7.2% | +1.6% | -1.1% | — |
| Feb 25, 2025 | BMO | 0.16 | 0.14 | -12.5% | 10.70 | +1.5% | +4.0% | -1.9% | +2.3% | +1.3% | -4.5% | — |
| Nov 7, 2024 | BMO | 0.12 | 0.13 | +8.3% | 14.50 | -1.5% | -3.0% | +1.4% | -1.1% | +0.5% | -1.1% | — |
| Aug 8, 2024 | BMO | 0.24 | 0.30 | +25.0% | 12.99 | -0.6% | +0.4% | +0.4% | +6.5% | +1.0% | +3.6% | — |
| May 8, 2024 | BMO | 0.27 | 0.34 | +24.1% | 16.89 | -0.4% | +1.8% | -1.2% | +0.0% | +0.4% | -0.2% | — |
| Feb 26, 2024 | BMO | 0.10 | 0.08 | -20.0% | 16.26 | +1.8% | +1.2% | -3.2% | -0.3% | +0.9% | +0.9% | — |
| Nov 7, 2023 | BMO | 0.12 | 0.18 | +50.0% | 10.70 | +0.0% | +1.4% | -5.4% | +4.1% | -1.2% | +7.5% | — |
| Aug 7, 2023 | BMO | 0.05 | 0.18 | +260.0% | 12.12 | +0.2% | +2.8% | -1.5% | -0.4% | -0.4% | -1.4% | — |
| May 9, 2023 | BMO | 0.29 | 0.45 | +55.2% | 9.31 | +1.4% | -3.3% | -2.3% | -2.5% | +3.9% | -4.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $26.38 | $26.56 | +0.7% | +1.7% | -2.4% | +0.8% | -1.2% | -4.6% |
| Feb 25 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $26.38 | $26.56 | +0.7% | +1.7% | -2.4% | +0.8% | -1.2% | -4.6% |
| Feb 24 | Leerink Partners | Maintains | Outperform → Outperform | — | $24.75 | $24.06 | -2.8% | +6.6% | +1.7% | -2.4% | +0.8% | -1.2% |
| Feb 19 | JP Morgan | Maintains | Overweight → Overweight | — | $24.78 | $25.04 | +1.0% | +1.7% | -0.9% | -0.9% | +6.6% | +1.7% |
| Jan 22 | Piper Sandler | Upgrade | Neutral → Overweight | — | $24.30 | $25.21 | +3.7% | +2.5% | -2.0% | +1.1% | -0.2% | -2.0% |
| Dec 18 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $22.08 | $22.30 | +1.0% | +0.0% | +1.0% | +0.0% | -0.4% | +0.7% |
| Nov 6 | UBS | Maintains | Buy → Buy | — | $21.60 | $21.74 | +0.6% | -0.4% | -0.1% | +3.6% | +2.6% | -3.5% |
| Oct 20 | UBS | Maintains | Buy → Buy | — | $21.42 | $21.59 | +0.8% | +1.4% | -0.5% | +0.1% | +0.6% | +1.3% |
| Oct 7 | JP Morgan | Upgrade | Neutral → Overweight | — | $20.66 | $21.12 | +2.2% | -1.0% | -0.5% | -1.3% | -1.5% | +1.4% |
| Sep 24 | Stifel | Maintains | Buy → Buy | — | $18.54 | $19.11 | +3.1% | +1.1% | +0.9% | +3.6% | +0.0% | +2.7% |
| Aug 11 | Piper Sandler | Maintains | Neutral → Neutral | — | $16.67 | $17.00 | +2.0% | +2.6% | +1.9% | +2.2% | +1.1% | -0.2% |
| Aug 8 | UBS | Maintains | Buy → Buy | — | $16.48 | $16.53 | +0.3% | +1.2% | +2.6% | +1.9% | +2.2% | +1.1% |
| Jul 23 | UBS | Maintains | Buy → Buy | — | $14.93 | $15.12 | +1.3% | +0.6% | -2.2% | +1.6% | -2.3% | -1.3% |
| Jul 17 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $14.51 | $14.95 | +3.0% | +3.1% | -1.2% | -0.7% | +1.7% | +0.6% |
| Jul 2 | Stifel | Maintains | Buy → Buy | — | $14.43 | $14.66 | +1.6% | +2.0% | -0.5% | -1.2% | +1.9% | +0.2% |
| Jun 26 | William Blair | Upgrade | Market Perform → Outperform | — | $13.76 | $14.21 | +3.3% | +3.9% | -0.1% | -0.1% | +1.1% | +2.0% |
| May 19 | Stifel | Maintains | Buy → Buy | — | $12.92 | $12.74 | -1.4% | +2.3% | -1.1% | -3.5% | +0.4% | -0.1% |
| May 8 | Stifel | Maintains | Buy → Buy | — | $12.01 | $12.08 | +0.6% | +2.2% | -2.6% | +7.2% | +1.6% | -1.1% |
| Apr 14 | Stifel | Maintains | Buy → Buy | — | $8.62 | $8.82 | +2.3% | +0.7% | -5.1% | -1.7% | +4.2% | +0.5% |
| Mar 6 | Piper Sandler | Maintains | Neutral → Neutral | — | $10.85 | $10.68 | -1.6% | -0.2% | +2.9% | -3.1% | -7.0% | +3.5% |
| Feb 26 | Barclays | Maintains | Overweight → Overweight | — | $10.70 | $10.86 | +1.5% | +4.0% | -1.9% | +2.3% | +1.3% | -4.5% |
| Feb 26 | UBS | Maintains | Buy → Buy | — | $10.70 | $10.86 | +1.5% | +4.0% | -1.9% | +2.3% | +1.3% | -4.5% |
| Feb 26 | Stifel | Maintains | Buy → Buy | — | $10.70 | $10.86 | +1.5% | +4.0% | -1.9% | +2.3% | +1.3% | -4.5% |
| Feb 26 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $10.70 | $10.86 | +1.5% | +4.0% | -1.9% | +2.3% | +1.3% | -4.5% |
| Feb 21 | Stifel | Maintains | Buy → Buy | — | $11.13 | $11.19 | +0.5% | -1.0% | +0.8% | -3.7% | +4.0% | -1.9% |
| Jan 29 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $12.17 | $12.14 | -0.2% | +1.0% | +1.5% | -3.5% | -2.6% | -1.8% |
| Jan 7 | Stifel | Maintains | Buy → Buy | — | $11.92 | $11.89 | -0.3% | -1.0% | -2.1% | -1.0% | +2.4% | +0.0% |
| Nov 8 | Barclays | Maintains | Overweight → Overweight | — | $14.50 | $14.28 | -1.5% | -3.0% | +1.4% | -1.1% | +0.5% | -1.1% |
| Oct 28 | Barclays | Maintains | Overweight → Overweight | — | $12.41 | $12.49 | +0.6% | +0.8% | +0.0% | +2.2% | -1.1% | -0.3% |
| Sep 23 | Barclays | Maintains | Overweight → Overweight | — | $14.07 | $14.17 | +0.7% | +2.6% | -3.9% | -1.6% | +0.5% | +4.3% |
| Sep 19 | Stifel | Maintains | Buy → Buy | — | $14.65 | $14.34 | -2.1% | +2.9% | -6.6% | +2.6% | -3.9% | -1.6% |
| Sep 19 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $14.65 | $14.34 | -2.1% | +2.9% | -6.6% | +2.6% | -3.9% | -1.6% |
| Jul 1 | Piper Sandler | Maintains | Neutral → Neutral | — | $14.43 | $14.46 | +0.2% | -2.3% | -0.6% | +0.9% | +0.6% | -2.0% |
| Jun 28 | Barclays | Maintains | Overweight → Overweight | — | $14.27 | $14.25 | -0.1% | +1.1% | -2.3% | -0.6% | +0.9% | +0.6% |
| May 13 | Piper Sandler | Maintains | Neutral → Neutral | — | $17.00 | $17.21 | +1.2% | +0.0% | +0.4% | -0.2% | -0.4% | +1.2% |
| May 9 | Barclays | Maintains | Overweight → Overweight | — | $16.89 | $16.82 | -0.4% | +1.8% | -1.2% | +0.0% | +0.4% | -0.2% |
| Mar 12 | Piper Sandler | Maintains | Neutral → Neutral | — | $16.02 | $16.09 | +0.4% | -1.6% | +0.9% | -1.0% | -0.2% | +0.4% |
| Feb 27 | Barclays | Maintains | Overweight → Overweight | — | $16.26 | $16.56 | +1.8% | +1.2% | -3.2% | -0.3% | +0.9% | +0.9% |
| Feb 27 | Morgan Stanley | Maintains | Overweight → Overweight | — | $16.26 | $16.56 | +1.8% | +1.2% | -3.2% | -0.3% | +0.9% | +0.9% |
| Feb 27 | Goldman Sachs | Maintains | Sell → Sell | — | $16.26 | $16.56 | +1.8% | +1.2% | -3.2% | -0.3% | +0.9% | +0.9% |
| Jan 17 | Goldman Sachs | Maintains | Sell → Sell | — | $15.13 | $14.90 | -1.5% | -2.2% | +0.0% | -1.4% | -0.4% | +1.2% |
| Jan 5 | Stifel | Upgrade | Hold → Buy | — | $14.55 | $15.46 | +6.3% | +6.2% | +0.6% | -0.9% | -1.3% | +1.8% |
| Dec 15 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $13.77 | $14.06 | +2.1% | -0.1% | -0.7% | +4.5% | -2.0% | +3.6% |
| Dec 7 | Stifel | Maintains | Hold → Hold | — | $12.87 | $13.06 | +1.5% | -0.8% | +0.2% | -0.7% | -0.2% | +7.6% |
| Nov 13 | Piper Sandler | Maintains | Neutral → Neutral | — | $10.68 | $10.68 | +0.0% | -1.2% | +7.5% | +0.6% | +0.7% | +2.9% |
| Nov 8 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $10.70 | $10.70 | +0.0% | +1.4% | -5.4% | +4.1% | -1.2% | +7.5% |
| Oct 30 | Stifel | Maintains | Hold → Hold | — | $8.85 | $8.89 | +0.5% | -0.5% | +0.0% | -2.0% | +8.6% | +2.6% |
| Aug 14 | Piper Sandler | Maintains | Neutral → Neutral | — | $12.17 | $12.12 | -0.4% | -1.4% | -1.9% | -2.0% | -0.7% | +1.4% |
| Aug 9 | Goldman Sachs | Maintains | Sell → Sell | — | $12.46 | $12.45 | -0.1% | -1.5% | -0.4% | -0.4% | -1.4% | -1.9% |
| Aug 8 | Goldman Sachs | Maintains | Sell → Sell | — | $12.12 | $12.15 | +0.2% | +2.8% | -1.5% | -0.4% | -0.4% | -1.4% |
No insider trades available.
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Abbott Laboratories' appointment of a new executive effective April 1, 2026, signals potential strategic shifts in operations or leadership direction that could affect near-term stock performance and investor confidence in company management.
Mar 18
8-K
Elanco Animal Health Incorporated -- 8-K Filing
Elanco Animal Health achieved 9% organic constant currency revenue growth in Q4, marking its 10th consecutive quarter of underlying growth, signaling strong execution of its growth and innovation strategy.
Feb 24
Data updated apr 25, 2026 6:49am
· Source: massive.com